These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26676909)

  • 21. Predictive Value of C-Reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
    Takahashi T; Jaber MM; Smith AR; Jacobson PA; Fisher J; Kirstein MN
    J Clin Pharmacol; 2022 Jul; 62(7):855-862. PubMed ID: 34970774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
    Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
    Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.
    Liu L; Zhou X; Wu T; Jiang H; Yang S; Zhang Y
    Int J Antimicrob Agents; 2017 Apr; 49(4):483-487. PubMed ID: 28159657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
    Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
    Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole: A Review of Population Pharmacokinetic Analyses.
    Shi C; Xiao Y; Mao Y; Wu J; Lin N
    Clin Pharmacokinet; 2019 Jun; 58(6):687-703. PubMed ID: 30687893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetics in China: The Dynamics of Intravenous Voriconazole in Critically Ill Patients with Pulmonary Disease.
    Chen W; Xie H; Liang F; Meng D; Rui J; Yin X; Zhang T; Xiao X; Cai S; Liu X; Li Y
    Biol Pharm Bull; 2015; 38(7):996-1004. PubMed ID: 26133710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosing and therapeutic drug monitoring of voriconazole in bottlenose dolphins (Tursiops truncatus).
    Ferrier K; van Elk CE; Bunskoek PE; van den Broek M
    Med Mycol; 2017 Feb; 55(2):155-163. PubMed ID: 27703023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES.
    Hyatt MW; Wiederhold NP; Hope WW; Stott KE
    J Zoo Wildl Med; 2017 Jun; 48(2):352-362. PubMed ID: 28749255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
    Dolton MJ; McLachlan AJ
    Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model.
    van den Born DA; Märtson AG; Veringa A; Punt NC; van der Werf TS; Alffenaar JC; Sturkenboom MGG; Touw DJ
    Int J Antimicrob Agents; 2023 Apr; 61(4):106750. PubMed ID: 36758777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does the Anesthetic Urethane Influence the Pharmacokinetics of Antifungal Drugs? A Population Pharmacokinetic Investigation in Rats.
    Azeredo FJ; Hass SE; Sansone P; Derendorf H; Costa TD; De Araujo BV
    J Pharm Sci; 2015 Oct; 104(10):3314-8. PubMed ID: 26087701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
    Kiser TH; Fish DN; Aquilante CL; Rower JE; Wempe MF; MacLaren R; Teitelbaum I
    Crit Care; 2015 Feb; 19(1):32. PubMed ID: 25645660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections.
    Dolton MJ; McLachlan AJ
    Curr Opin Infect Dis; 2014 Dec; 27(6):493-500. PubMed ID: 25229352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
    Sasaki T; Tabuchi H; Higuchi S; Ieiri I
    Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to: "Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach".
    Zane NR; Thakker DR
    Clin Pharmacokinet; 2015 May; 54(5):569-72. PubMed ID: 25735635
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.
    Mori M; Kobayashi R; Kato K; Maeda N; Fukushima K; Goto H; Inoue M; Muto C; Okayama A; Watanabe K; Liu P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1004-13. PubMed ID: 25451051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.